Medicine Maker: Drug Containment Considerations for Bringing Mrna Drugs Successfully to the Market
In the last two years, mRNA technology has come to the attention of the world as a result of the COVID-19 pandemic. Although
researchers have been investigating this technology for the last couple of decades, until now its application in commercial
drugs has been limited. The COVID-19 pandemic accelerated the adoption of mRNA technology and opened the door
to a broad field of drug therapies, and it is probable that more mRNA drugs will be commercialized and make a positive
impact on our overall health care system. Leading mRNA pharma companies have started working on expanding their mRNA-based drug pipeline with other
prophylactic vaccines against infectious diseases, including shingles and flu. Other therapeutic classes, such as rare diseases
and oncology, could also benefit from this breakthrough technology. These drugs will need a primary packaging container
for storage, transport and injection. A number of considerations will influence the selection of the drug containment solution to ensure that the primary
container contributes to the success of the drug launch.
